CAS 347396-82-1

Ranibizumab

Description:

Ranibizumab is a recombinant humanized monoclonal antibody fragment that specifically targets vascular endothelial growth factor A (VEGF-A), a key protein involved in angiogenesis and vascular permeability. It is primarily used in the treatment of various eye conditions, such as age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina. Ranibizumab is characterized by its small size compared to full-length antibodies, which allows for better tissue penetration. The substance is administered via intravitreal injection, and its mechanism of action involves binding to VEGF-A, preventing it from interacting with its receptors on endothelial cells, thereby reducing vascular leakage and neovascularization. The molecular weight of ranibizumab is approximately 48 kDa, and it is produced using recombinant DNA technology in a mammalian cell expression system. Stability and storage conditions are critical for maintaining its efficacy, as it is sensitive to light and temperature variations. Overall, ranibizumab represents a significant advancement in targeted therapy for ocular diseases.

Formula: C₁₁H₁₂N₂O₂

Synonyms:

• RanibizumabQ: What is
• Ranibizumab
• Ranibizumab USP/EP/BP
• Ranibizumab (anti-VEGF)
• Lucentis
• Research Grade Ranibizumab(DHD12601)
• Ranibizumab Q: What is the storage condition of
• Ranibizumab Q: What is the CAS Number of
• Unii-zl1R02vt79
• Ranibizumab - 25mg/ml solution in PBS

Ranibizumab

CAS: 347396-82-1

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121,

Purity: 98%

Color and Shape: Liquid

Molecular weight: 149.19KD

Ref: TM-T9928

Ranibizumab - 10mM histidine - histidine HCL buffer

CAS: 347396-82-1

Ranibizumab is a recombinant monoclonal antibody that binds to the active site of vascular endothelial growth factor (VEGF) and neutralizes its biological activity. It is used as a research tool to study the function of VEGF and in pharmacology to inhibit angiogenesis. Ranibizumab is also used to treat age-related macular degeneration, diabetic retinopathy, and neovascular glaucoma.

Purity: Min. 95 Area-%

Ref: 3D-R-4200

Ranibizumab - 10mM histidine- histidine HCl buffer

CAS: 347396-82-1

Ranibizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks its action. It is used in the treatment of age-related macular degeneration and other diseases characterized by neovascularization, such as diabetic retinopathy and retinopathy of prematurity. Intravitreal ranibizumab injections have been shown to be effective for neovascular age-related macular degeneration, with a reduction in choroidal neovascularization and visual acuity improvement demonstrated in clinical trials. This drug has also been shown to reduce the incidence of new lesions in the retina and choroid, as well as to reduce or delay the development of new vessels. Ranibizumab is administered by intravitreal injection, which means it is injected into the vitreous humor inside the eye. The medication can be given alone or with bevacizumab (another VEG

Purity: Min. 95 Area-%

Color and Shape: Clear Liquid

Ref: 3D-BR171775

Ranibizumab - 25mg/ml solution in PBS

CAS: 347396-82-1

Monoclonal antibody to VEGF-A

Color and Shape: Powder

Ref: 3D-FR139132